Evaluating Upadacitinib in the Treatment of Moderate-to-Severe Active Ulcerative Colitis: Design, Development, and Potential Position in Therapy

Upadacitinib is a selective small molecule that inhibits Janus kinase (JAK) type 1. This molecule is administrated orally and is currently approved for the treatment of rheumatoid arthritis, atopic dermatitis, and psoriatic arthritis. Upadacitinib has been approved by the United States Food and Drug...

Descripción completa

Detalles Bibliográficos
Autores principales: Napolitano, Maria, D’Amico, Ferdinando, Ragaini, Elisa, Peyrin-Biroulet, Laurent, Danese, Silvio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9211104/
https://www.ncbi.nlm.nih.gov/pubmed/35747444
http://dx.doi.org/10.2147/DDDT.S340459

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9211104/
https://www.ncbi.nlm.nih.gov/pubmed/35747444
http://dx.doi.org/10.2147/DDDT.S340459

Ejemplares similares